In a study appearing in Nature Chemistry, researchers at the University of California, Davis Institute for Psychedelics and Neurotherapeutics (IPN) report the successful total synthesis of ibogaine, ibogaine analogues and related compounds from pyridine — a relatively inexpensive and widely available chemical.

Delix Therapeutics recently announced that the first neuroplastogen drug based on UC Davis Institute for Psychedelics and Neurotherapeutics (IPN) research will be tested in patients with major depressive disorder.

New research shows that the anti-anxiety and hallucinogenic-like effects of a psychedelic drug work through different neural circuits. The study, in a mouse model, shows that it could be possible to separate treatment from hallucinations when developing new drugs based on psychedelics.

A new study shows how children’s and adolescents’ memories of the COVID lockdowns of 2020 and 2021 changed over time and related to their mental health.

UC Davis researchers unveil CaST, a tool that rapidly tags neurons affected by psychedelics, offering insights into therapeutic mechanisms.

Earlier this year, a team of researchers from the UC Davis Institute for Psychedelics and Neurotherapeutics revealed in Science that psychedelics spur cortical neuron growth by activating intracellular pools of 5-HT2A receptors. This neuroplasticity combats the withering dendritic spines characteristic of several neuropsychiatric disorders.